Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial ; volume:18 ; number:1 ; day:6 ; month:9 ; year:2016 ; pages:1-10 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (6.9.2016), 1-10, 12.2016
- Creator
-
Strand, Vibeke
- Contributor
-
Kosinski, Mark
Chen, Chieh-I
Joseph, George
Rendas-Baum, Regina
Graham, Neil M. H.
van Hoogstraten, Hubert
Bayliss, Martha
Fan, Chunpeng
Huizinga, Tom
Genovese, Mark C.
SpringerLink (Online service)
- DOI
-
10.1186/s13075-016-1096-9
- URN
-
urn:nbn:de:1111-2016100613250
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Strand, Vibeke
- Kosinski, Mark
- Chen, Chieh-I
- Joseph, George
- Rendas-Baum, Regina
- Graham, Neil M. H.
- van Hoogstraten, Hubert
- Bayliss, Martha
- Fan, Chunpeng
- Huizinga, Tom
- Genovese, Mark C.
- SpringerLink (Online service)
Other Objects (12)
Methotrexate intolerance in Rheumatoid Arthritis
Methotrexate
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS)
Genetic variations in methotrexate metabolic pathway genes influence methotrexate responses in rheumatoid arthritis patients in Malaysia
Validation of Methotrexate Intolerance Severity Score (MISS) questionnaire to measure methotrexate intolerance among rheumatoid arthritis Egyptian patients
High-dose Methotrexate
METHOTREXATE INDUCED LEUCOENCEPHALOPATHY
Methotrexate intolerance in Rheumatoid Arthritis
Methotrexate
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS)
Genetic variations in methotrexate metabolic pathway genes influence methotrexate responses in rheumatoid arthritis patients in Malaysia
Validation of Methotrexate Intolerance Severity Score (MISS) questionnaire to measure methotrexate intolerance among rheumatoid arthritis Egyptian patients
High-dose Methotrexate
METHOTREXATE INDUCED LEUCOENCEPHALOPATHY
Methotrexate intolerance in Rheumatoid Arthritis
Methotrexate
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS)
Genetic variations in methotrexate metabolic pathway genes influence methotrexate responses in rheumatoid arthritis patients in Malaysia
Validation of Methotrexate Intolerance Severity Score (MISS) questionnaire to measure methotrexate intolerance among rheumatoid arthritis Egyptian patients
High-dose Methotrexate